Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†. Ann Oncol 2014
Dec 15, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
Dec 15, 2014
Ann Oncol 2014
van Soest R J, Tannock I F, Eisenberger M A, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F E, Templeton Arnoud, De Wit R
more
